Amneal Pharmaceuticals, Inc. AMRX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net revenue by Business | |||||
| Affordable Medicines | $1.75B+3.6% | $1.69B+14.5% | $1.47B+2.7% | $1.43B— | |
| AvKARE | $744.73M+12.3% | $662.95M+24.7% | $531.75M+30.9% | $406.11M+16.4% | |
| Other Operating Income by Business | |||||
| Affordable Medicines | $5.24M— | $0-100% | $1.14M-71.3% | $3.96M— | |
| AvKARE | $0— | $0— | $0— | —— | |
| Gross Profit by Business | |||||
| Affordable Medicines | $683.92M+1.5% | $673.9M+20.9% | $557.53M+4.0% | $536.04M— | |
| AvKARE | $146.79M+41.7% | $103.61M+19.3% | $86.85M+52.4% | $56.98M-13.9% | |
| Specialty | $282.59M+16.3% | $242.93M+37.9% | $176.18M-8.1% | $191.69M+3.8% | |
| Operating Income (Loss) by Business | |||||
| Affordable Medicines | $380.8M+41.0% | $270.1M-2.2% | $276.17M+23.2% | $224.16M— | |
| AvKARE | $83.62M+94.9% | $42.9M+36.1% | $31.51M+850% | $3.32M-51.2% | |
| SG&A by Business | |||||
| Affordable Medicines | $142.38M+9.9% | $129.58M+8.1% | $119.91M+9.2% | $109.78M— | |
| AvKARE | $63.18M+4.1% | $60.71M+9.7% | $55.34M+3.1% | $53.66M-7.4% | |
| Gain (Loss) from Litigation Settlement by Business | |||||
| AvKARE | $0— | $0— | $0— | $0— | |
| Other by Business | |||||
| Affordable Medicines | $28.41M-6.1% | $30.25M-0.5% | $30.41M-20.2% | $38.1M— | |
| Specialty | $5.58M+115% | $2.59M-55.6% | $5.84M+8.1% | $5.41M— | |
| Restructuring and other charges by Business | |||||
| Affordable Medicines | $2.97M+4,144% | $70K-66.8% | $211K-74.3% | $821K— | |
| AvKARE | $0— | $0— | $0— | $0— | |
| Currency translation by Business | |||||
| Affordable Medicines | -$1.97M— | —— | -$224K— | —— | |
| AvKARE | $0— | —— | $0— | —— | |
| Specialty | $0— | —— | $0— | —— | |
| Product development and studies by Business | |||||
| Affordable Medicines | $3.45M-8.6% | $3.78M-55.2% | $8.43M-63.7% | $23.2M— | |
| Specialty | $8.52M+505% | $1.41M-52.5% | $2.97M+36.0% | $2.18M— | |
| Regulatory fees by Business | |||||
| Affordable Medicines | $6.4M+16.6% | $5.49M-38.5% | $8.91M+60.9% | $5.54M— | |
| Specialty | $0— | $0-100% | $2.02M-35.1% | $3.12M— | |
| Cost of goods sold by Business | |||||
| Affordable Medicines | $1.06B+5.0% | $1.01B+10.7% | $913.87M+2.0% | $896.03M— | |
| AvKARE | $597.94M+6.9% | $559.34M+25.7% | $444.9M+27.4% | $349.13M+23.4% | |
| Materials and supplies by Business | |||||
| Affordable Medicines | $31.57M-22.2% | $40.59M+89.8% | $21.38M-35.0% | $32.91M— | |
| Specialty | $3M+145% | $1.22M-76.1% | $5.11M+291% | $1.31M— | |
| R&D by Business | |||||
| Affordable Medicines | $156.01M-9.2% | $171.77M+29.9% | $132.23M-21.1% | $167.51M— | |
| AvKARE | $0— | $0— | $0— | $0— | |
| Goodwill by Business | |||||
| Affordable Medicines | $643.21M-1.0% | $649.66M-0.4% | $652.45M-1.0% | $659.08M+31.4% | |
| AvKARE | $277.86M0.0% | $277.9M0.0% | $277.97M0.0% | $277.97M-0.5% | |
| Specialty | $1.47B0.0% | $1.47B0.0% | $1.47B+33.0% | $1.1B+0.8% | |
| Employee compensation and benefits by Business | |||||
| Affordable Medicines | $54.37M+16.8% | $46.55M-1.3% | $47.19M-9.2% | $51.95M— | |
| Specialty | $43.71M+25.2% | $34.91M-4.0% | $36.35M+4.2% | $34.89M— | |
| Facilities costs by Business | |||||
| Affordable Medicines | $6.83M+1.8% | $6.71M-10.3% | $7.49M-20.4% | $9.4M— | |
| Specialty | $1.96M-66.6% | $5.86M+3.6% | $5.66M+53.7% | $3.68M— | |
| Milestones by Business | |||||
| Specialty | $6M— | $0— | $0-100% | $4.5M— | |
| Intellectual property legal development expenses by Business | |||||
| Affordable Medicines | $7.39M+30.0% | $5.69M+53.3% | $3.71M-12.8% | $4.25M— | |
| AvKARE | $0— | $0— | $0— | $0— | |
| Specialty | $243K— | —— | $120K+12.1% | $107K-30.5% | |
| Net revenue by Product | |||||
| Auto-Injector | $232.8M+11.1% | $209.5M+30.2% | $160.85M+14.4% | $140.56M— | |
| Biosimilar | $100.23M-20.1% | $125.42M+90.3% | $65.92M+1,934% | $3.24M— | |
| Central nervous system | $333.42M+19.0% | $280.17M— | —— | —— | |
| Distribution | $408.46M-5.9% | $433.98M+24.9% | $347.41M+33.3% | $260.56M+35.1% | |
| Government label | $270.11M+68.9% | $159.96M+31.3% | $121.83M+24.0% | $98.23M-17.0% | |
| Hormonal / allergy | $154.93M+18.8% | $130.43M— | —— | —— | |
| Injectable | $161.24M-2.5% | $165.43M+16.6% | $141.85M-24.9% | $188.94M— | |
| Institutional | $35.38M-17.2% | $42.75M+12.5% | $38.02M+37.0% | $27.74M+10.2% | |
| International | $12.13M+35.4% | $8.95M+313% | $2.17M+47.5% | $1.47M— | |
| Oral liquid | $72.82M-29.6% | $103.42M-6.9% | $111.05M+2.4% | $108.41M— | |
| Oral solid | $726.38M+5.4% | $689.44M+6.1% | $650M-0.4% | $652.74M— | |
| Other dosage forms | $252.42M+24.8% | $202.19M+12.0% | $180.48M-13.8% | $209.41M— | |
| Other therapeutic classes | $39.66M+38.6% | $28.62M— | —— | —— | |
| Subtotal dosage forms | $1.73B+3.4% | $1.68B+14.1% | $1.47B+3.3% | $1.42B— | |
| Subtotal therapeutic classes | $528.01M+20.2% | $439.22M+12.5% | $390.46M+4.4% | $374.12M— | |
| Transdermal | $187.51M+3.6% | $180.92M+13.7% | $159.08M+33.4% | $119.29M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
